Lancet Diabetes Endocrinol: Cardiovascular, Mortality, and Renal Outcomes in Patients with Type 2 Diabetes Treated with GLP-1 Receptor Agonists-A systematic review and meta-analysis of randomized trials

Two types of anti-glycemic drugs-GLP-1 receptor agonists and SGLT2 inhibitors can reduce the risk of high-risk patients with type 2 diabetesHeart vascular events
.

GLP-1 receptor agonists reduce glycosylated hemoglobin (HbA1c), improve blood pressure and variably reduce weight without increasing the risk of hypoglycemia

Two types of anti-glycemic drugs-GLP-1 receptor agonists and SGLT2 inhibitors can reduce the risk of high-risk patients with type 2 diabetesHeart vascular events

GLP-1 receptor agonists can reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes

The researchers conducted a meta-analysis that included new data from Amplay-O, using a random effects model to estimate the overall hazard ratio (HR) of MACE; its components; all-cause mortality; hospitalization due to heart failure; combined renal outcome, Including the development of massive proteinuria, a doubling of serum creatinine, or an estimated glomerular filtration rate (EGFR) drop of at least 40%, renal replacement therapy or death from kidney disease; deterioration of renal function based on changes in EGFR; and key safety results The odds ratio
.

The incidence of MACE in the placebo group, the presence or absence of cardiovascular disease, HbA1c level, trial duration, treatment dose interval, structural homology with human GLP-1 or Exendin-4, BMI, age, and EGFR were also used to examine patients' subtypes.

The researchers conducted a meta-analysis that included new data from Amplay-O, using a random effects model to estimate the overall hazard ratio (HR) of MACE; its components; all-cause mortality; hospitalization due to heart failure; combined renal outcome, Including the development of massive proteinuria, a doubling of serum creatinine, or an estimated glomerular filtration rate (EGFR) drop of at least 40%, renal replacement therapy or death from kidney disease; deterioration of renal function based on changes in EGFR; and key safety results The odds ratio

• The results of 98 articles were screened, 8 trials, and 60080 patients met the pre-specified criteria and were included
  
  GLP-1 receptor agonists, regardless of their structural homology, can reduce the risk of a single MACE component, all-cause mortality, heart failure hospitalization, and deterioration of renal function in patients with type 2 diabetes
  
  Literature source: https://doi.
  80599.
  net/10.
  1016/s2213-8587(21)00203-5 Literature source: https://doi.
  80599.
  net/10.
  1016/s2213-8587(21)00203-5 https: //doi.
  80599.
  net/10.
  1016/s2213-8587(21)00203-5 leave a message here